EP4159199A1 — Combined formulation of mirabegron and solifenacin
Assigned to Lotus Pharmaceutical Co Ltd · Expires 2023-04-05 · 3y expired
What this patent protects
The present invention provides a combined pharmaceutical form comprising - a first component containing modified-release mirabegron or a pharmaceutically acceptable salt thereof, preferably extended-release mirabegron or a pharmaceutically acceptable salt thereof, and - a secon…
USPTO Abstract
The present invention provides a combined pharmaceutical form comprising - a first component containing modified-release mirabegron or a pharmaceutically acceptable salt thereof, preferably extended-release mirabegron or a pharmaceutically acceptable salt thereof, and - a second component containing immediate-release solifenacin or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
- Myrbetriq (MIRABEGRON) · Apgdi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.